中国生物技术CARsgen油墨应对上海癌症研究所的候选人焦点

StephenW

2. China biotech CARsgen inks deal with Shanghai Cancer Institute on candidate focus
      By EJ Lane     Comment | Forward | Twitter | Facebook | LinkedIn

China clinical stage biotech CARsgen signed a 5-year partnership agreement with the Shanghai Cancer Institute to develop CARsgen's chimeric antigen receptor T-cell (CAR-T) immunotherapeutics.

The pact, according to a news release, includes efforts to identify and develop novel CAR-T candidates and next generation technologies with CARsgen getting rights to any drugs.

In March, the Shanghai-based firm started a Phase I clinical study of its glypican 3 (GPC3) CAR-T therapy in patients with refractory hepatocellular carcinoma (HCC), the company said in the press release.

"To date, 6 patients with relapsed and/or refractory HCC have been enrolled and treated with escalating doses of GPC3-CAR-T infusions (up to ~1.1x109 cells)," the release said in an update on the trial.

"Two of the 6 patients demonstrated more than a 90% decline in levels of alpha-fetoprotein (AFP), a liver biomarker indicating the activity of liver cancer. Glypican 3 is expressed in a variety of tumors, with a high frequency in HCC. In in vivo and in vitro preclinical studies, GPC3-CAR-T effectively killed GPC3 positive HCC cells."

Clinical work will be carried out with Renji Hospital in Shanghai.

In December last year, CARsgen completed an undisclosed A round to finance its work in CAR-T immunotherapies for a variety of cancers. Teaming up with the Shanghai Cancer Institute and Shanghai Renji Hospital, the company plans to spend its funding on clinical trials for its lead therapy, targeting hepatocellular carcinoma.

The company said in its release that it "has a broad range of CAR-T candidates for lung, brain and stomach cancers as well as blood cancers. CARsgen and Renji Hospital began enrolling up to 10 patients in a Phase 1 clinical study of an anti-EGFR CAR-T therapy designed to treat glioblastoma multiforme (GBM or brain cancer)."

Other China-focused companies such as Nasdaq-listed biotech Cellular Biomedicine Group ($CBMG) are working on Phase I clinical efforts in CAR-T immuno-oncology clinical development programs, a complex field that in many respects requires substantial investment in basic research for proof, but still has caught attention as a cutting-edge look at potential oncology therapies.

- here's the release

StephenW

2.中国生物技术CARsgen油墨应对上海癌症研究所的候选人焦点
  通过EJ巷评论|转发|微博| Facebook的| LinkedIn

中国临床阶段的生物技术CARsgen签署了上海癌症研究所一个5年的合作协议，共同开发CARsgen的嵌合抗原受体T细胞（CAR-T）免疫治疗。

该协议，根据新闻发布，包括努力确定和开发新的CAR-T候选人和下一代技术与CARsgen获得权利对任何药物。

在3月份，上海的一家公司开始了第一阶段，该公司在新闻稿中称，其3肌醇蛋白聚糖（GPC3）CAR-T治疗难治性肝细胞癌（HCC）的临床研究。

“到目前为止，6例复发和/或难治性肝癌已被录取，并与不断升级的剂量GPC3-CAR-T输液治疗（可达〜1.1x109细胞），”在庭审的最新情况发布会上说。

“两个6例的证明比甲胎蛋白（AFP），肝的生物标志物，指示肝癌的活性的水平下降90％以上。磷脂酰肌醇聚糖3表达于各种肿瘤，在肝癌的高频。在体内和体外临床前研究，GPC3-CAR-T有效地杀死GPC3阳性肝癌细胞。“

临床工作将开展与仁济医院的上海。

去年十二月，CARsgen完成了一个未公开的A轮融资其CAR-T免疫治疗工作，为多种癌症。联手与上海癌症研究所和上海仁济医院，该公司计划花费其资金上的临床试验其领先疗法，靶向肝癌。

该公司在其新闻稿中说，它“具有广泛的CAR-T候选人肺，脑和胃的癌症以及血癌。CARsgen和仁济医院开始招募最多10名患者在抗一期临床研究-EGFR CAR-T疗法用于治疗胶质母细胞瘤（GBM或脑癌）“。

其他关注中国的企业如在纳斯达克上市的生物细胞生物医学集团（$ CBMG）正在研究阶段的CAR-T免疫肿瘤学临床开发项目I期临床的努力，一个复杂的领域，在许多方面需要对基础研究的大量投资证明，但还是抓住了注意，因为尖端看看潜在的肿瘤治疗方法。

- 这里的释放